Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Head & Neck 1Endocrine 1Dermatologic 1

Conditions

Melanoma 12Lymphoma, T-Cell, Cutaneous 5Mycosis Fungoides 4Sezary Syndrome 3Lung Neoplasms 3Endometrial Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Uveal Melanoma 2Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Ovarian Neoplasms 2Multiple Myeloma 2Lymphoma, T-Cell 2Carcinoma, Renal Cell 2Carcinoma, Merkel Cell 2Carcinoma, Hepatocellular 2Uterine Neoplasms 1Urogenital Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Skin Neoplasms 1Rectal Neoplasms 1Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Neoplasm Metastasis 1

Interventions

pembrolizumab 2atezolizumab 2Nivolumab 2entinostat 1durvalumab 1cemiplimab 1bemcentinib 1avelumab 1Polymerase Chain Reaction 1Microarray Analysis 1Levoleucovorin 1Leucovorin 1Ipilimumab 1Interleukin-2 1In Situ Hybridization, Fluorescence 1Immunoglobulin G 1Immunoenzyme Techniques 1Immune Checkpoint Inhibitors 1Gene Expression Profiling 1Flow Cytometry 1Fentanyl 1Etoposide 1Docetaxel 1Disulfides 1Cyclophosphamide 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Mesothelioma, Malignant × Immunoglobulin G × Dermatologic × Clear all
NCT03074513 2026-03-11

Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
133 enrolled
DermatologicEndocrineHead & NeckOther solid neoplasmThoracic

Nasopharyngeal Carcinoma, Mesothelioma, Malignant, Adenocarcinoma, Mucinous, Adenoma, Islet Cell, Nasopharyngeal Neoplasms, Carcinoma, Merkel Cell, Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon âš¡